Oncolytics Biotech (TSE:ONC) PT Raised to C$3.50

Oncolytics Biotech (TSE:ONC) had its price objective lifted by investment analysts at Raymond James from C$3.00 to C$3.50 in a research report issued on Friday, BayStreet.CA reports. Raymond James’ price target suggests a potential upside of 177.78% from the stock’s current price.

Oncolytics Biotech Trading Down 2.3 %

TSE ONC opened at C$1.26 on Friday. Oncolytics Biotech has a one year low of C$1.20 and a one year high of C$3.10. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a market capitalization of C$96.84 million, a price-to-earnings ratio of -3.32 and a beta of 1.38. The company’s 50-day simple moving average is C$1.35 and its two-hundred day simple moving average is C$1.42.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) EPS for the quarter, hitting analysts’ consensus estimates of C($0.10). Equities analysts forecast that Oncolytics Biotech will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.